Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)

Status Terminated

Clinical Trial Summary

Main objective:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT), delays tumoral spread and increases progression-free survival.

Secondary objectives:

To evaluate whether the subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting with the onset of chemotherapy, increases global survival, improving the response rates to treatment with CT + RT (radiotherapy) and reduces the incidence of venous thromboembolism (VTE).

Clinical Trial Description

There is clinical evidence indicative of the beneficial effects of heparin in the evolution of patients with cancer. Apart from the studies that in an indirect way demonstrated an increase in the survival of oncological patients who, because of presenting a venous thromboembolism episode, were treated with low molecular weight heparin (LMWH) in comparison with those treated with non-fractionated heparin; direct actions were also demonstrated from the use of heparin in the survival and tumour progression. The administration of LMWH together with Chemotherapy has been proved to increase the survival of patients diagnosed of cancer of the pancreas in relation to those only treated with chemotherapy. An increase in the global survival of advanced solid tumours, with no thromboembolic disease,has also been showed.

All this suggests that an improvement in the survival of patients is observed when heparin is added to the usual anti-tumour treatment, especially to those without spread disease, and this effect seems to be independent of the protection against the thromboembolic complications. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00324558
Study type	Interventional
Source	Clinica Universidad de Navarra, Universidad de Navarra
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2005
Completion date	September 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01860898` - A Phase I Study of iPS Cell Generation From Patients With COPD	N/A
Completed	`NCT00046787` - Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer	Phase 2
Recruiting	`NCT03212404` - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	Phase 1
Recruiting	`NCT03554473` - M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers	Phase 1/Phase 2
Terminated	`NCT00094978` - Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum	Phase 1
Recruiting	`NCT04162041` - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer	Phase 2
Completed	`NCT03092739` - A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
Completed	`NCT00305942` - Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT00359359` - A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer	Phase 1/Phase 2
Completed	`NCT00191750` - A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned	Phase 2
Recruiting	`NCT05461430` - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Recruiting	`NCT02366741` - Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study	N/A
Active, not recruiting	`NCT01900951` - Temozolomide as Maintenance Therapy in Small Cell Lung Cancer	Phase 2
Completed	`NCT00826644` - Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient	Phase 3
Completed	`NCT00284154` - Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer	Phase 2
Recruiting	`NCT00100256` - Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy	Phase 1/Phase 2
Completed	`NCT00126828` - Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer	Phase 1/Phase 2
Terminated	`NCT02034123` - Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma	Phase 1
Recruiting	`NCT05500391` - Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring	Phase 2
Recruiting	`NCT02688036` - Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC	Phase 3